AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Streetinsider

Published November 9, 2026

Delix Therapeutics Closes Oversubscribed $100 Million Series C Financing to ... - StreetInsider

Read the full story at Streetinsider

Delix has reverse-engineered and optimized psychedelics , designing novel medicines that promote rapid and sustained therapeutic efficacy through.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Psychedelic press release